AIM ImmunoTech Inc. (AIM)

Market Cap	12.66M
Revenue (ttm)	190,000
Net Income (ttm)	-23.93M
Shares Out	63.32M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,002,616
Open	0.190
Previous Close	0.180
Day's Range	0.180 - 0.200
52-Week Range	0.160 - 0.620
Beta	-0.36
Analysts	Strong Buy
Price Target	3.00 (+1,400.0%)
Earnings Date	Nov 15, 2024

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 28
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: AIM
• Website: https://aimimmuno.com

Financial Performance

In 2023, AIM ImmunoTech's revenue was $202,000, an increase of 43.26% compared to the previous year's $141,000. Losses were -$28.96 million, 48.9% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AIM stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 1,400.00% from the latest price.

Price Target

$3.0

(1,400.00% upside)

Analyst Consensus: Strong Buy